All In Biotech

Drug Trial Radar · NCT05497336

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

An Open-label, Multicenter, Phase Ib/III Study of Efficacy and Safety of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

8

Actual

Start

Aug 18, 2022

Primary completion

Jan 24, 2025

Study completion Jan 24, 2025

Sponsor

Sponsor type
Industry
First posted
Aug 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b consists of combined dose escalation phase and dose expansion phase. Phase 3 study will compare efficacy and safety of IBI351 combined with cetuximab versus chemotherapy in treatment of KRAS G12C-mutated metastatic colorectal cancer

Conditions

  • Colorectal Cancer

Interventions

  • IBI351Drug

    IBI351 is administered orally

  • CetuximabDrug

    Cetuximab is administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of DLTs (Dose-limiting Toxicity) in the Combined Dose Escalation PhaseTime frame: 28 days during the first 4-week cycle
  2. Objective response rate (ORR)Time frame: Up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.